BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

Genentech sent a letter to FDA requesting a hearing on the agency's proposal in December to withdraw the approval of Avastin bevacizumab for first-line treatment of HER2-negative metastatic breast cancer. By Jan. 18, Genentech plans to submit information to be used at the...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >